Targeting RET-rearranged non-small-cell lung cancer: future prospects

Código QR

Targeting RET-rearranged non-small-cell lung cancer: future prospects

Giuseppe Bronte, Paola Ulivi, Alberto Verlicchi, Paola Cravero, Angelo Delmonte, Lucio Crinò Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy Abstract: Non-small-cell lung cancer (NSCLC) patients with mutate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bronte G, Ulivi P, Verlicchi A, Cravero P, Delmonte A, Crinò L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	RET non-small cell lung cancer multi-kinase inhibitors gene rearrangement Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fea97887badd4d81a5d99fd0ca558a2b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
por: Rossi G, et al.
Publicado: (2017)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
por: Umberto Caterino, et al.
Publicado: (2021)

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
por: Yaogeng Wang, et al.
Publicado: (2021)

Rare, Endangered and Threatened (RET) climbers of Southern Western Ghats, India
por: Sarvalingam,Ariyan, et al.
Publicado: (2016)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Somatic Mutations in Exons 10, 11, and 16 of the RET Protooncogene in Medullary Thyroid Carcinoma Patients
por: Elham Shakiba, et al.
Publicado: (2020)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang L, et al.
Publicado: (2021)

Conditional Deletion of Activating Rearranged During Transfection Receptor Tyrosine Kinase Leads to Impairment of Photoreceptor Ribbon Synapses and Disrupted Visual Function in Mice
por: Wei-Hao Peng, et al.
Publicado: (2021)

Oligoprogression in Non-Small Cell Lung Cancer
por: Daijiro Harada, et al.
Publicado: (2021)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin E, et al.
Publicado: (2018)

Germline RET Leu56Met Variant Is Likely Not Causative of Multiple Endocrine Neoplasia Type 2
por: Anna Reimer Hansen, et al.
Publicado: (2021)

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
por: Tran PN, et al.
Publicado: (2016)

Chromosomal Rearrangements and Altered Nuclear Organization: Recent Mechanistic Models in Cancer
por: Concetta Federico, et al.
Publicado: (2021)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti F, et al.
Publicado: (2019)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee CS, et al.
Publicado: (2020)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain RK, et al.
Publicado: (2017)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
por: Weiguo Gu, et al.
Publicado: (2021)

Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy
por: Yiqun Zhang, et al.
Publicado: (2021)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Chi‐Hao Wu, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

ASSOCIATION OF DNA REPAIR GENE POLYMORPHISM WITH CHROMOSOMAL ABERRATIONS IN THE BLOOD LYMPHOCYTES OF PATIENTS WITH LUNG CANCER
por: V. I. Minina, et al.
Publicado: (2012)

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Ling Peng, et al.
Publicado: (2021)

Impact of Sodium Dichloroacetate Alone and in Combination Therapies on Lung Tumor Growth and Metastasis
por: Aya Al-Azawi, et al.
Publicado: (2021)

Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
por: Yu-Mu Chen, et al.
Publicado: (2021)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Modifier Role of Common <i>RET</i> Variants in Sporadic Medullary Thyroid Carcinoma
por: Anna Skalniak, et al.
Publicado: (2021)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

Targeted Therapies in Cancer: To Be or Not to Be, Selective
por: Skye Montoya, et al.
Publicado: (2021)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Liesbeth M. Hondelink, MD, et al.
Publicado: (2021)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel D, et al.
Publicado: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero Estela, et al.
Publicado: (2020)

Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations
por: Jara,Lilian, et al.
Publicado: (2017)

Amide-Assisted Rearrangement of Hydroxyarylformimidoyl Chloride to Diarylurea
por: Xizhong Song, et al.
Publicado: (2021)

Condensed tannin reactivity inhibition by internal rearrangements: Detection by CP-MAS 13C NMR
por: Navarrete,P, et al.
Publicado: (2011)

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock AB, et al.
Publicado: (2020)

The Mitochondrial Genomes of 18 New Pleurosticti (Coleoptera: Scarabaeidae) Exhibit a Novel trnQ-NCR-trnI-trnM Gene Rearrangement and Clarify Phylogenetic Relationships of Subfamilies within Scarabaeidae
por: Sam Pedro Galilee Ayivi, et al.
Publicado: (2021)